Pedro Cardoso-Teixeira

Dr. Pedro Cardoso-Teixeira

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2025 in Ophthalmology and Therapy
Verified
Journal Article
Open access
PDF file
JAJoão Alves Ambrósio
João Alves Ambrósio
PCPedro Cardoso-Teixeira
Pedro Cardoso-Teixeira
MGMariana Garcia
Mariana Garcia
JCJoão Chibante-Pedro
João Chibante-Pedro
MRMiguel Ruão
Miguel Ruão
Introduction Diabetic macular edema (DME) imposes a substantial clinical and psychosocial burden on patients and caregivers due to frequent visits and intravitreal treatments. The fluocinolone acetonide intravitreal implant (Iluvien®) offers sustained drug delivery for up to 3 years. We assessed its real-world impact on vision, macular anatomy, intraocular pressure (IOP), quality of life (QoL), and treatment burden, including caregiver impact. Methods Prospective, real-world observational study of 41 patients with previously treated DME. Assessments occurred at baseline and at 6, 12, 18, 24, and 30 months. Outcomes included best-corrected visual acuity (BCVA), central macular thickness (CMT), IOP, and National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) composite scores. Burden metrics included clinic visits per year and caregiver accompaniment/absenteeism. Results At baseline, mean BCVA was 0.42 ± 0.30 logMAR, CMT 415.8 ± 106.5 µm, IOP 16.6 ± 4.1 mmHg, and NEI VFQ-25 67.6 ± 16.4; 46.3% of patients required caregiver accompaniment, and 61% reported pre-injection anxiety (median duration 2 days). At last follow-up, mean BCVA improved to 0.29 ± 0.26 logMAR (≈+6–7 ETDRS letters; p < 0.001), CMT decreased to 368.1 ± 79.6 µm (p = 0.002), and IOP remained stable at 16.7 ± 4.1 mmHg. The NEI VFQ-25 increased to 77.0 ± 18.0, with a significant main effect of time (repeated-measures analysis of variance (ANOVA), p = 0.001; partial η2 = 0.675); improvements were evident by 6 months and sustained through 30 months (all comparisons p < 0.05). Clinic visits declined from 5.8 ± 1.6 to 3.7 ± 1.5 per year (p < 0.001). Conclusions In a prospective real-world setting, Iluvien was associated with durable improvements in vision, macular anatomy, and QoL, with stable IOP. Treatment reduced the frequency of clinic visits and procedures, alleviating patient burden and caregiver absenteeism. These findings support Iluvien as a patient-centered, long-acting therapy for chronic DME and motivate multicenter validation and health-economic studies that incorporate caregiver outcomes.

29 October 2025 in Advances in Ophthalmology & Visual System
Verified
Journal Article
Open access
PDF file
JAJoão Alves Ambrósio
João Alves Ambrósio
PCPedro Cardoso-Teixeira
Pedro Cardoso-Teixeira
JJJeniffer Jesus
Jeniffer Jesus
CACatarina Pestana Aguiar
Catarina Pestana Aguiar
IAInês Almeida
Inês Almeida
JCJoão Chibante
João Chibante
Objective: Pseudoexfoliation syndrome (PEX) is an age-related systemic disorder characterised by the deposition of extracellular fibrillar material in ocular tissues, particularly the lens capsule, pupillary margin, and trabecular meshwork. PEX is a major risk factor for glaucoma and elevated intraocular pressure (IOP), but its independent effect on corneal endothelial morphology remains uncertain. Previous studies have reported inconsistent findings regarding endothelial cell density (ECD), morphology, and central corneal thickness (CCT). This study aimed to evaluate the impact of PEX on endothelial morphology and CCT using non-contact specular microscopy in a Portuguese cohort. Material and methods: We conducted a retrospective cross-sectional study including 450 eyes: 250 with PEX and 200 age-matched controls without PEX. Eyes with pre-existing corneal disease, prior intraocular surgery, or contact lens wear were excluded. PEX was diagnosed by slit-lamp biomicroscopy, and IOP was measured by Goldmann applanation tonometry. Endothelial parameters were assessed with the EM-3000 specular microscope, including cell count, ECD, mean cell area, coefficient of variation (CV), hexagonality, and CCT. Group differences were analysed using parametric and non-parametric tests, with ANCOVA adjusting for age, sex, and IOP. Results: Baseline characteristics were comparable for age (PEX: 76.2 ± 6.9 years; controls: 75.9 ± 6.1 years; p = 0.289) and sex (female: 56.4% vs. 55.5%; p = 0.521). Glaucoma and ocular hypertension were more frequent in PEX (35.5% and 5.2%, respectively) compared with controls (3.9% and 0%; p < 0.001). On unadjusted analysis, ECD was lower in PEX eyes (2389.2 ± 305.7 vs. 2461.8 ± 274.1 cells/mm²; p = 0.042), though the difference attenuated after adjustment (p = 0.055). Mean cell area was larger in PEX (417.0 µm² [IQR 386.0–452.0] vs. 410.5 µm² [381.0–439.0]) and reached significance after adjustment (p = 0.036). CV was slightly lower in PEX (37.8% [35.0–42.5] vs. 40.9% [36.5–45.0]; p = 0.029), persisting after adjustment (p = 0.031). Hexagonality did not differ between groups. CCT was significantly greater in PEX (541.0 ± 35.9 vs. 530.2 ± 36.8 µm; p = 0.029), remaining significant after adjustment (p = 0.041). Conclusion: PEX was associated with subtle but clinically relevant corneal endothelial changes, including a trend toward reduced ECD, larger cell area, lower CV, and increased CCT. These alterations persisted for CCT, CV, and cell area after adjustment for age, sex, and IOP. The higher prevalence of glaucoma and ocular hypertension in PEX further reinforces the need for careful preoperative assessment. Specular microscopy should be considered routine in PEX patients to anticipate surgical risks and guide management.

30 March 2025
Verified
Journal Article
Open access
JAJoão Alves Ambrósio
João Alves Ambrósio
CACatarina Pestana Aguiar
Catarina Pestana Aguiar
PCPedro Cardoso-Teixeira
Pedro Cardoso-Teixeira
VMVítor Miranda
Vítor Miranda
JPJoão Chibante Pedro
João Chibante Pedro
MRMiguel Ruão
Miguel Ruão
Birdshot chorioretinopathy (BCR) is a chronic, bilateral posterior uveitis characterized by yellow-white fundus lesions and a strong association with HLA-A29. Visual decline, often due to cystoid macular edema (CME) and retinal atrophy, necessitates early immunomodulatory therapy. This case report describes the clinical course of BCR and highlights the role of intravitreal corticosteroids in managing inflammation and CME. A 54-year-old previously healthy male diagnosed with BCR based on clinical findings and a positive HLA-A29 test presented with refractory CME. Over 20 months, his best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were monitored. Initial treatment included topical corticosteroids, methotrexate, and oral corticosteroids to address anterior chamber reaction, vitritis, diffuse retinal lesions, and vasculitis. Cyclosporine was added for persistent inflammation but discontinued due to a cutaneous reaction. Despite these efforts, CME persisted, necessitating intravitreal corticosteroids. BCVA in the right eye (OD) fluctuated between 20/20 and 20/30, while the left eye (OS) ranged from 20/20 to 20/40, with changes linked to treatment adjustments. Recurrent CME episodes were more pronounced in the OS, where CFT varied from 328 to 637 µm, while OD values ranged from 304 to 576 µm. Intravitreal dexamethasone and fluocinolone implants reduced CFT in both eyes, achieving stabilization at the final assessment (OD 341 µm, OS 347 µm). This case illustrates the challenges of managing BCR with refractory CME. While systemic immunomodulatory therapy is foundational, intravitreal corticosteroids play a vital role in controlling CME and preserving visual function. Combining systemic and local therapies proved essential for disease control. Long-term monitoring and individualized treatment are critical in managing this chronic condition.

22 January 2026 in Cureus
Verified
Journal Article
Open access
PCPedro Cardoso-Teixeira
Pedro Cardoso-Teixeira
JAJoão Alves Ambrósio
João Alves Ambrósio
MGMariana Garcia
Mariana Garcia
JCJoão Chibante-Pedro
João Chibante-Pedro
LFLígia Figueiredo
Lígia Figueiredo

11 October 2026 in Eye & ENT Research
Verified
Journal Article
Open access
PCPedro Cardoso-Teixeira
Pedro Cardoso-Teixeira
JAJoão Alves Ambrósio
João Alves Ambrósio
CACatarina Pestana Aguiar
Catarina Pestana Aguiar
MCMiguel Campos‐Lopes
Miguel Campos‐Lopes
JCJoão Chibante‐Pedro
João Chibante‐Pedro
JCJoão Cardoso Costa
João Cardoso Costa

18 September 2026 in Eye
Verified
Journal Article
Closed access
PDF file
PCPedro Cardoso-Teixeira
Pedro Cardoso-Teixeira
LDLilianne Duarte
Lilianne Duarte
CFCláudia Costa Ferreira
Cláudia Costa Ferreira